The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
Publications
Churg-Strauss and montelukast.
International journal of immunopathology and pharmacology 2011 Oct-Dec;24;1079-82 — 2011 Oct-Dec — 1079-82
Montelukast and Churg-Strauss syndrome.
Swiss medical weekly 2004 Jun 26;134;377-80 — 2004 Jun 26 — 377-80
Pulmonary eosinophilia associated with montelukast.
Thorax 1999 Jun;54;558-60 — 1999 Jun — 558-60
Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment.
Lancet (London, England) 1999 Feb 27;353;725-6 — 1999 Feb 27 — 725-6